A patient with multiple sclerosis (MS) presents with worsening muscle weakness, numbness, and episodes of blurred vision. The neurologist plans to start corticosteroid therapy. Which nursing intervention is the priority to address the patient's current symptoms and potential complications?

C) Assess the patient's mobility and implement safety measures to prevent falls.

A) Educate the patient about the importance of regular eye exams to monitor for optic neuritis.

B) Monitor the patient's blood pressure closely to manage her hypertension effectively.

C) Assess the patient's mobility and implement safety measures to prevent falls.

D) Instruct the patient on proper administration techniques for interferon beta-1a therapy.

A patient with multiple sclerosis (MS) presents with increased muscle weakness, numbness, and episodes of blurred vision. Recent neurological examination shows brisk reflexes and a positive Babinski sign. What is the priority nursing intervention to address these symptoms?

B) Administer prescribed corticosteroids to manage acute exacerbations.

A) Educate the patient about the importance of a low-sodium diet to manage hypertension.

B) Administer prescribed corticosteroids to manage acute exacerbations.

C) Encourage regular physical exercise to improve muscle strength.

D) Monitor liver function tests regularly due to potential medication side effects.

A patient with multiple sclerosis has shown new lesions on an MRI and persistent hypertension. The healthcare team is considering transitioning the patient to natalizumab. What is the most important nursing consideration when monitoring this patient after the medication change?

A) Monitoring for signs of progressive multifocal leukoencephalopathy (PML)

B) Ensuring the patient follows a low-sodium diet

C) Encouraging increased physical activity to reduce fatigue

D) Assessing for changes in visual acuity daily

A patient with multiple sclerosis (MS) is experiencing persistent fatigue and elevated blood pressure despite recent adjustments in her treatment regimen. Which nursing intervention is most appropriate to address these issues while considering the patient's overall condition?

B) Educate the patient on the importance of a low-sodium diet to help manage blood pressure.

A) Encourage the patient to increase caffeine intake to combat fatigue.

B) Educate the patient on the importance of a low-sodium diet to help manage blood pressure.

C) Advise the patient to engage in high-intensity exercise to reduce fatigue.

D) Recommend the patient to take over-the-counter sleep aids to improve rest.

A patient on natalizumab therapy presents with increased fatigue, dizziness, and elevated liver enzymes. Considering these symptoms and her current treatment plan, what is the most appropriate nursing intervention to prioritize?

C) Perform a fall risk assessment and implement safety precautions.

A) Discontinue natalizumab immediately and inform the healthcare provider.

B) Educate the patient on dietary modifications to manage hypertension.

C) Perform a fall risk assessment and implement safety precautions.

D) Schedule an immediate liver biopsy to assess hepatic function.

A patient recently started on natalizumab reports increased fatigue and occasional dizziness. Her ALT levels have risen slightly, and her blood pressure remains elevated despite an ACE inhibitor. Which nursing intervention is most appropriate to prioritize at this time?

C) Initiate fall precautions and recommend physical therapy to address mobility concerns.

A) Educate the patient on the importance of adhering to a low-sodium diet to manage hypertension.

B) Schedule weekly liver function tests to monitor for hepatic stress due to natalizumab.

C) Initiate fall precautions and recommend physical therapy to address mobility concerns.

D) Discuss with the healthcare provider about adjusting the antihypertensive medication regimen.

A patient with multiple sclerosis is experiencing balance instability and elevated liver enzymes while on natalizumab. Which nursing intervention should be prioritized to address the patient's immediate safety needs?

B) Implement fall precautions and provide a cane for mobility support

A) Educate the patient about energy conservation techniques

B) Implement fall precautions and provide a cane for mobility support

C) Monitor liver function tests and report significant changes immediately

D) Coordinate with the healthcare provider to adjust antihypertensive medication

A patient with multiple sclerosis is experiencing elevated liver enzymes and balance instability, and her blood pressure is not well-controlled despite starting a calcium channel blocker. Which of the following interventions should the nurse prioritize to address the patient's current health concerns?

C) Implement safety measures to prevent falls due to the patient's balance instability.

A) Educate the patient on the importance of adhering to dietary modifications for hypertension management.

B) Collaborate with the healthcare provider to adjust the patient's natalizumab dosage due to elevated liver enzymes.

C) Implement safety measures to prevent falls due to the patient's balance instability.

D) Schedule more frequent blood pressure monitoring to evaluate the effectiveness of the current antihypertensive regimen.

A patient with a history of multiple sclerosis and hypertension presents with increased dizziness and elevated liver enzymes. Given the changes in her medication regimen, which nursing intervention is most appropriate to prioritize?

A) Monitor for signs of multiple sclerosis exacerbation and report any neurological changes immediately.

B) Educate the patient on maintaining a low-sodium diet to support blood pressure control.

C) Schedule liver function tests more frequently to monitor hepatotoxicity.

D) Encourage the patient to increase fluid intake to help manage dizziness.

A patient with a history of multiple sclerosis is experiencing increased dizziness and unsteadiness. The healthcare team has decided to temporarily discontinue natalizumab due to worsening hepatotoxicity and adjust the antihypertensive regimen. Which nursing intervention is most appropriate to address the patient's current symptoms and medication changes?

B) Monitor the patient's blood pressure and educate them on how to manage dizziness at home.

A) Educate the patient about the importance of regular liver function tests and schedule the next test.

B) Monitor the patient's blood pressure and educate them on how to manage dizziness at home.

C) Reinforce the need to restart natalizumab if symptoms of multiple sclerosis worsen.

D) Advise the patient to avoid salt in their diet to further control their blood pressure.

multiple sclerosis - Nursing Case Study

Pathophysiology

• Primary mechanism: Multiple sclerosis (MS) is characterized by an autoimmune attack on the central nervous system, where immune cells mistakenly target and destroy the myelin sheath—a protective layer around nerve fibers—leading to impaired nerve signal transmission.

• Secondary mechanism: In response to the myelin damage, the body can initiate an inflammatory process. This inflammation further exacerbates nerve tissue damage, resulting in the formation of scar tissue (sclerosis) that disrupts normal neuron function.

• Key complication: Over time, the cumulative effect of demyelination and scarring can lead to irreversible nerve damage, resulting in a range of neurological symptoms such as muscle weakness, coordination problems, and cognitive impairments.

Patient Profile

Demographics:

42-year-old female, software engineer

History:

• Key past medical history: Diagnosed with relapsing-remitting multiple sclerosis 5 years ago, hypertension

• Current medications: Interferon beta-1a, lisinopril, vitamin D supplements

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing difficulty with mobility and coordination

• Key symptoms: Muscle weakness, fatigue, numbness in the legs, occasional blurred vision, mild cognitive difficulties

• Vital signs: Blood pressure 150/95 mmHg, heart rate 88 bpm, respiratory rate 18 breaths per minute, temperature 98.6°F

Section 1

New Complications:

Over the past two weeks, the patient has experienced a notable increase in symptoms, prompting further investigation. She reports a significant worsening of muscle weakness and numbness in her legs, now extending to her arms. Her fatigue has intensified, making routine activities increasingly difficult. Additionally, her blurred vision episodes have become more frequent and longer-lasting, raising concerns about potential optic neuritis, a common complication associated with MS. During a recent follow-up appointment, the patient's blood pressure was recorded at 160/98 mmHg, suggesting that her hypertension is not well-controlled, which could further complicate her condition.

A comprehensive neurological examination reveals a decrease in proprioception and vibratory sensation in her lower extremities. Reflexes are brisk, and there is a positive Babinski sign, indicating upper motor neuron involvement. These findings suggest that her MS may be progressing, with increased demyelination and possible new lesions in critical areas of the central nervous system. An MRI of the brain and spinal cord is ordered to assess for new or enlarging lesions, providing insight into the current status of her disease.

The patient's recent laboratory results show a slight elevation in liver enzymes, which could be a side effect of her interferon beta-1a therapy. Her vitamin D levels remain within the therapeutic range, indicating compliance with supplementation. Given the progression of her symptoms and potential optic neuritis, her neurologist is considering initiating corticosteroid therapy to manage acute exacerbations and reduce inflammation. This approach aims to address her current symptoms while reassessing her overall treatment plan to better manage her chronic condition and prevent further deterioration.

Section 2

Following the initiation of corticosteroid therapy, the patient's clinical team closely monitors her response to the intervention. Over the course of the first week, there is a slight but encouraging improvement in her muscle strength, particularly in her upper limbs, allowing her to perform daily tasks with less assistance. However, the numbness in her legs persists, and she continues to experience episodes of blurred vision, albeit with reduced frequency. The patient's fatigue remains a significant challenge, impacting her overall quality of life despite the adjusted treatment regimen.

New diagnostic results from the recent MRI reveal the presence of several new lesions in the cervical spinal cord, correlating with her increased upper limb symptoms. These findings indicate active inflammation and progression of her multiple sclerosis, necessitating a reevaluation of her long-term management plan. The MRI also suggests mild enhancement of the optic nerve, supporting the diagnosis of optic neuritis. Given these developments, her neurologist recommends transitioning from interferon beta-1a to a more aggressive disease-modifying therapy, such as natalizumab, to better control her MS activity and prevent future relapses.

In light of the elevated liver enzymes observed previously, the healthcare team decides to conduct a thorough review of the patient's current medications to rule out potential hepatotoxicity. The patient's blood pressure remains elevated, recorded at 158/95 mmHg during a recent visit. This persistent hypertension prompts the consideration of additional antihypertensive agents to mitigate cardiovascular risks and support her overall health. These adjustments aim to stabilize her condition and enhance her functional status, setting the stage for ongoing monitoring and tailored interventions as her journey with multiple sclerosis continues.

Section 3

As the patient's treatment plan is adjusted to include natalizumab, her healthcare team closely monitors for any signs of new complications, particularly those related to the medication's side effects and her pre-existing conditions. Within two weeks of initiating natalizumab, the patient reports experiencing increased fatigue and occasional dizziness, prompting a more detailed clinical assessment. Her recent laboratory tests reveal a slight elevation in liver enzymes, with ALT levels rising to 65 U/L from a previous 48 U/L, suggestive of mild hepatic stress. Given her history of elevated liver enzymes, the team decides to implement weekly liver function tests to closely monitor any further changes.

In addition, the patient's blood pressure remains elevated, despite the introduction of a low-dose ACE inhibitor. Her latest reading stands at 160/98 mmHg, indicating insufficient control with the current antihypertensive regimen. The team considers introducing a calcium channel blocker to the treatment plan to better manage her blood pressure and reduce cardiovascular risk. This decision is made in conjunction with dietary recommendations, emphasizing reduced sodium intake and increased potassium-rich foods to support her cardiovascular health.

The patient's persistent numbness in her legs, coupled with the new symptoms of dizziness, raises concerns about her mobility and fall risk. A physical therapy assessment is ordered to evaluate her gait and balance, and recommendations are made for assistive devices to enhance her safety during daily activities. The team also explores potential benefits of occupational therapy to address her fatigue and optimize energy conservation techniques, aiming to improve her quality of life and functional independence. As these interventions are implemented, ongoing evaluation will be crucial to determine their effectiveness and adjust the management plan as needed.

Section 4

Following the implementation of the revised treatment plan, the patient undergoes an initial assessment by the physical therapy team. The evaluation reveals significant balance instability, with the patient struggling to maintain a steady gait. Her Berg Balance Scale score is 36 out of 56, indicating a moderate fall risk. The physical therapist notes that the patient's proprioception is impaired, particularly in her lower extremities, which contributes to her difficulty in walking without support. As a result, the therapist recommends the use of a cane to aid in mobility and suggests a tailored exercise program focusing on strengthening and balance improvement. Additionally, occupational therapy sessions are initiated to address her fatigue, where she is introduced to energy conservation techniques, such as task prioritization and planned rest periods.

Concurrent with these therapeutic interventions, the patient's clinical team observes a concerning trend in her liver function tests. Over the following week, her ALT level rises further to 78 U/L, and her AST increases to 55 U/L, raising alarms about potential hepatotoxicity from natalizumab. The team considers the risks and benefits of continuing the medication, given its role in managing her multiple sclerosis symptoms, and contemplates a potential dose adjustment or a switch to an alternative therapy. Meanwhile, her blood pressure remains stubbornly high, with readings averaging 158/96 mmHg, despite the introduction of the calcium channel blocker. This necessitates a closer review of her antihypertensive regimen and emphasizes the importance of adherence to dietary modifications.

As the team evaluates these developments, they remain vigilant for any emerging signs of progressive multifocal leukoencephalopathy (PML), a rare but serious complication associated with natalizumab. A thorough neurological exam is conducted, which fortunately shows no new focal deficits or changes in cognitive function at this time. However, the patient's increasing fatigue and occasional dizziness, coupled with her elevated liver enzymes, underscore the complexity of managing her condition and highlight the need for ongoing, multifaceted care. The healthcare team plans to reassess the effectiveness of the current interventions and consider adjustments to her treatment strategy in the upcoming follow-up appointment.

Section 5

During the follow-up appointment, the patient's condition presents a new complication that demands immediate attention. The patient reports episodes of increased dizziness and a generalized feeling of unsteadiness, which have become more frequent over the past few days. These symptoms are particularly concerning given her history of balance instability. Upon examination, her blood pressure is found to be 162/98 mmHg, slightly higher than previous readings, suggesting that her hypertension remains uncontrolled despite medical management. Additionally, a repeat liver function test reveals a continuing upward trend in liver enzymes, with ALT now at 95 U/L and AST at 68 U/L, indicating worsening hepatotoxicity.

In light of these developments, the clinical team is prompted to reconsider the current medication regimen. The possibility of natalizumab contributing to the hepatotoxicity is weighed against its benefits in controlling her multiple sclerosis. Given the persistent hypertension, there's a need to re-evaluate the effectiveness of the current antihypertensive medications and potentially introduce an additional agent or switch classes to achieve better blood pressure control. The patient's dizziness may be multifactorial, potentially exacerbated by both her hypertension and the side effects of her medications, necessitating a careful review of her complete pharmacological profile.

The team decides to temporarily discontinue natalizumab while closely monitoring her neurological status for any signs of exacerbation. A liver function panel will be repeated in one week to assess for improvement. Meanwhile, her antihypertensive regimen is adjusted to include an ACE inhibitor alongside the existing calcium channel blocker to better manage her blood pressure. These changes aim to stabilize her condition while minimizing further complications, setting the stage for a reassessment of her treatment plan in the next follow-up. As her clinical picture evolves, the healthcare team remains poised to adapt their approach to ensure optimal management of her complex needs.